Rapid tumor growth was observed in all animals regardless of either treatment (Figure 2B), suggesting that antitumor activity against HER2-expressing D2F2/E2 tumor cells was due to HER2-specific immune responses induced by scFvNLDC-145-HER2. Here, ERBB2 is linked to neoplasm.